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EDITORIAL   
Preventing Sudden Death in Idiopathic Dilated 
Cardiomyopathy: A Difficult to Settle Issue  
Antonis S. Manolis, MD  
Third Department of Cardiology, Athens University 
School of Medicine, Athens, Greece/E-mail: asm@otenet.gr  
Abstract 
Risk stratification for sudden cardiac death in non-ischemic 
dilated cardiomyopathy remains a difficult and controversial 
issue. This is currently guided by left ventricular ejection 
fraction, severity of heart failure symptoms according to New 
York Heart Association classification, and the morphology and 
duration of the QRS complex. The results of a recent study 
stirred some initial controversy with regards to the utility of the 
implantable cardioverter defibrillator in these patients, however, 
a subsequent meta-analysis confirmed prior findings of the 
survival-prolonging benefit of device therapy. These issues are 
herein briefly reviewed. Rhythmos 2017;12(1):1-6.   
Key Words: sudden cardiac death; dilated cardiomyopathy; 
implantable cardioverter defibrillator; ventricular tachyarrhythmias; 
heart failure; cardiac resynchronization therapy   
Abbreviations: CMR = cardiac magnetic resonance (imaging); DCM 
= dilated cardiomyopathy; ECG = electrocardiogram; ICD = 
implantable cardioverter defibrillator; LGE = late gadolinium 
enhancement; LV = left ventric-le(-ular); LVEF = LV ejection fraction; 
NYHA = New York Heart Association; QUALY = quality-adjusted 
life-year; SCD = sudden cardiac death; VF = ventricular fibrillation; VT 
= ventricular tachycardia   
Introduction 
Risk stratification for sudden cardiac death (SCD) in 
non-ischemic dilated cardiomyopathy (DCM) remains a 
hard task for clinicians.1 According to a meta-analysis to 
estimate the performance of 12 commonly reported risk 
stratification tests as predictors of arrhythmic events in 
patients with nonischemic DCM, comprising 45 studies 
enrolling 6,088 patients with a mean left ventricular 
ejection fraction (LVEF) of 30.6+11.4%, none of the 
autonomic tests (heart rate variability, heart rate 
turbulence, baroreflex sensitivity) were significant 
predictors of arrhythmic outcomes.1  The best predictors of 
adverse outcomes included T-wave alternans, left 
ventricular end-diastolic diameter, electrophysiology 
study (EPS), signal-averaged ECG, LVEF, QRS duration, 
and non-sustained ventricular tachycardia (VT).  
Current guidelines for implantable cardioverter 
defibrillator (ICD) implantation in patients with non-
ischemic DCM rely solely on the imprecise parameters of 
depressed LVEF and NYHA functional class, criteria that 
are neither specific nor sensitive enough to adequately 
capture the highest risk patients.2-6 Cardiac 
resynchronization therapy (CRT) is further relied upon the 
morphology and duration of the QRS complex.7 
Nevertheless, survival in patients with idiopathic DCM has 
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improved substantially over the last decades; DCM 
patients have a better outcome than previously reported 
when treated according to current guidelines, including 
optimal medical therapy and ICD implantation.8    
Prior ICD Trials (Table 1) 
The Cardiomyopathy Trial (CAT) (2002), comprising 
104 patients with recent onset of DCM (< 9 months) and 
an LVEF < 30%, randomly assigned to the implantation of 
an implantable cardioverter-defibrillator (ICD) (n=50) or 
control (n=54), did not provide evidence in favor of 
prophylactic ICD implantation in patients with DCM of 
recent onset and impaired LVEF.9   
Also, according to the AMIOVIRT trial (2003), 
comprising 103 patients with DCM, LVEF <35% and 
asymptomatic non-sustained VT, randomized to ICD 
(n=51) vs amiodarone (n=52), mortality and quality of life 
in patients with non-ischemic DCM and non-sustained VT 
treated with amiodarone or an ICD were not statistically 
different.10  There was a trend towards a more beneﬁcial 
cost proﬁle and improved arrhythmia-free survival with 
amiodarone therapy.  
According to the Marburg Cardiomyopathy Study 
(MACAS), comprising 343 patients with idiopathic DCM, 
reduced LVEF and lack of beta-blocker use were important 
arrhythmia risk predictors in DCM, whereas signal-
averaged ECG, baroreflex sensitivity, heart rate 
variability, and T-wave alternans were not helpful for 
arrhythmia risk stratification.11    
The DEFINITE trial enrolled 458 patients with non-
ischemic DCM, a LVEF of <35% (mean 21%), and 
premature ventricular complexes or nonsustained VT, 
randomized to standard therapy (n=229) or standard 
therapy plus ICD (n=229).12  Over 29+14 months, there 
was a nonsignificant reduction in total death rate with 28 
deaths in the ICD group and 40 in the control group (hazard 
ratio, 0.65; P=0.08), with 2-year mortality rate of 14.1% in 
the standard-therapy group (annual mortality rate, 7 
percent) and 7.9% in the ICD group. However, the risk of 
sudden death was significantly reduced, with 3 sudden 
deaths in the ICD group, as compared with 14 in the 
standard-therapy group (hazard ratio, 0.20; P=0.006).   
Although the role of EPS in DCM patients has been 
limited and controversial,13-15 the DEFINITE trial and 
other investigators have indicated that inducibility of either 
VT or ventricular fibrillation (VF) may be associated with 
an increased likelihood of subsequent ICD therapy for VT 
or VF.16, 17  Specifically, according to the DEFINITE trial, 
at follow-up, 34.5% of the inducible group (10 of 29) 
experienced ICD therapy for VT or VF or arrhythmic death 
versus 12% (21 of 175) noninducible patients (hazard ratio 
= 2.60, P = 0.014).16  
Based on all the above trials, considered underpowered 
to detect differences in survival, it was not clear whether 
ICD implantation was of real benefit to DCM patients with 
regards to a reduction of total mortality. This was only 
shown by a subsequent study, the SCD-HeFT trial, which 
randomized 2521 patients with NYHA class II (70%) or III 
(30%) CHF and a LVEF of <35% to conventional heart 
failure therapy plus placebo (847 patients), conventional 
therapy plus amiodarone (845 patients), or conventional 
therapy plus an ICD (829 patients).18 However, this study 
was not a pure DCM trial, as it included both ischemic 
(52%) and non-ischemic (48%) heart failure patients with 
a median LVEF of 25%. Over a median follow-up of 45.5 
months, there were 244 deaths (29%) in the placebo group, 
240 (28%) in the amiodarone group, and 182 (22%) in the 
ICD group. As compared with placebo, amiodarone was 
associated with a similar risk of death (hazard ratio, 1.06; 
P=0.53) and ICD therapy was associated with a decreased 
risk of death of 23 percent (0.77; P=0.007) and an absolute 
decrease in mortality of 7.2% points after 5 years in the 
overall population. Results did not vary according to either 
ischemic or nonischemic causes of CHF, but they did vary 
according to the NYHA class, thus the conclusion was that 
in ischemic or non-ischemic patients with NYHA class II 
or III heart failure symptoms and LVEF of <35%, 
amiodarone has no favorable effect on survival, whereas 
ICD therapy reduces overall mortality by 23%.  
Hence, based on the results of the SCD-HeFT trial, 
subsequent and recent guidelines have adopted the 
recommendation for ICD implantation for primary 
prevention of SCD in DCM patients with a LVEF <35% 
and NYHA class II-III, despite ≥3 months of treatment 
with optimal pharmacological therapy who are expected to 
survive for >1 year with good functional status.3, 5, 6    
A CRT trial (COMPANION) also evaluated ischemic 
and non-ischemic (41-46%) patients (total N=1520) with 
advanced heart failure (NYHA class III or IV) and a QRS 
interval of >120 ms, randomly assigned (1:2:2 ratio) to 
optimal pharmacologic therapy alone or in combination 
with CRT with either a pacemaker or an ICD.19 As 
compared with optimal therapy alone, CRT with a 
pacemaker decreased the risk of the primary end point 
(time to death from or hospitalization for any cause) by 
34% (hazard ratio-HR, 0.81; P=0.014), as did CRT with an 
ICD by 40% (HR, 0.80; P=0.01). However, total mortality 
was reduced non-significantly by the pacemaker (24%; 
P=0.059), and significantly by the ICD (36%; P=0.003).  
There was also a CRT trial employing only a CRT 
pacemaker without an ICD (CARE-HF) which included 
813 (43-48% DCM) heart failure patients with NYHA 
class III or IV, LVEF <35% and cardiac dyssynchrony, 
who were randomized to medical therapy alone or with 
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CRT.20 Over a mean of 29.4 months, the primary end point 
(time to death from any cause or an unplanned 
hospitalization) was reached in 39% in the CRT group vs 
55% in the medical-therapy group (HR, 0.63; P<0.001). 
Mortality was 20% in the CRT group compared with 30% 
in the medical group (hazard ratio 0.64; P<0.002).  
Recent guidelines were also based on a pooled analysis 
of 5 primary prevention trials (1854 patients with non-
ischemic DCM) demonstrating a statistically significant 
31% reduction in all-cause mortality for ICD relative to 
medical therapy (RR 0.69, P = 0.002).21  Mortality 
reduction remained significant even after elimination of 
the CRT-D trial (RR 0.74, P = 0.02). Indications for ICD 
and CRT device implantation in patients with DCM are 
summarized in Table 2.   
Current Data 
Doubt on the efficacy of ICD in prolonging total 
survival in DCM patients was recently cast by the 
DANISH trial, which randomized 1116 patients with 
symptomatic systolic heart failure (LVEF ≤35%) to an 
ICD (n=556) or usual clinical care (n= 560; control group). 
In both groups, 58% of the patients received CRT.22 Over 
a median follow-up period of 67.6 months, total mortality 
rate was 21.6% in the ICD group and 23.4% in the control 
group (hazard ratio, 0.87; P = 0.28). Nevertheless, the SCD 
rate was 4.3% in the ICD group and 8.2% in the control 
group (hazard ratio, 0.50; P = 0.005). As the accompanying 
editorial of this trial indicates,23  the finding of no 
significant benefit in overall mortality in the DANISH trial 
was a result of the low risk of SCD among the patients 
included in the trial. This low risk reflects the fact that 
DCM patients have lower rates of SCD and total mortality 
compared to ischemic patients, and also the effect of 
optimal medical therapy that these patients were receiving, 
including a large percentage of patients (58%) also fitted 
with a CRT device.  
Most recently, the DANISH trial was included in a new 
meta-analysis, which showed that the benefit of ICD 
implantation in DCM patients still remains solid.24 
Specifically, this meta-analysis comprised 6 randomized 
controlled trials, enrolling 2,970 patients with DCM, that 
studied the efficacy of ICD for primary prevention. Pooled 
analysis of these 6 trials (including those with CRT-D) 
demonstrated a statistically significant 23% risk reduction 
in all-cause mortality in favor of ICD therapy (HR 0.77). 
In addition, a separate analysis of trials that assessed ICD 
plus optimal therapy vs optimal therapy alone (after 
exclusion of trials that involved patients with CRT-D), a 
statistically significant 24% reduction was found in all-
cause mortality with ICD (HR 0.76).  
As a considerable percentage of patients diagnosed 
with DCM, estimated at ~30%, may show partial or full 
recovery of the LV function with medical therapy, with 
consequent favorable prognosis, a minimal 3-month period 
of medical therapy has been suggested to precede formal 
evaluation and recommendation for ICD implantation.25 
Furthermore, LV functional recovery may continue well 
beyond this 3-month period, obviating the need for device 
implantation. LGE cardiac magnetic resonance imaging 
(CMR) has been suggested as a tool to evaluate for the 
presence or absence of myocardial fibrosis and the 
likelihood of reverse remodeling, and also follow DCM 
patients for longer periods of time under medical treatment 
before a decision is made for ICD implantation.26 One 
should also be conservative for DCM patients with a 
potentially reversible etiology, such as alcohol-related 
DCM, peripartum cardiomyopathy, or possible 
myocarditis. A major drawback of this ICD deferring 
approach is the unknown risk of SCD lurking during this 
waiting period.  
Indeed, during the early period of ICD approval for 
primary prevention in DCM patients, a 9-month time 
restriction was applied by regulatory authorities based on 
earlier studies.27  However, this did not pan out in 
subsequent studies,27 and this time qualifier is not reflected 
in the current American guidelines, which state that “ICD 
therapy should be considered in such patients provided that 
a reversible cause of transient LV function has been 
excluded and their response to optimal medical therapy has 
been assessed. The optimal time required for this 
assessment is uncertain…use of a time qualifier relative to 
the time since diagnosis of a nonischemic DCM may not 
reliably discriminate patients at high risk for SCD in this 
selected population”.2, 3  
However, according to current ESC guidelines, 
implantation of an ICD for primary prevention is not 
recommended within the first 3 months after initial 
diagnosis of non-ischemic CM.6  Specifically, the 2016 
ESC heart failure guidelines state that “an ICD is 
recommended to reduce the risk of sudden death and all-
cause mortality in patients with symptomatic heart failure 
(NYHA Class II–III), and an LVEF ≤35% despite ≥3 
months of optimal medical therapy, provided they are 
expected to survive substantially longer than 1 year with 
good functional status”.6 The expectation is that recovery 
of left ventricular function may occur during this period. If 
not, implantation of an ICD for primary prevention can be 
useful following this 3-month waiting period after initial 
diagnosis of non-ischemic CM. To circumvent such 
restrictions, an HRS/ACC/AHA Expert Consensus 
document recommends ICD implantation in the following 
situations:28  patients <9 months from the initial diagnosis 
of DCM who require nonelective permanent pacing, who 
would meet primary prevention criteria for implantation of 
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an ICD, and recovery of LV function is uncertain or not 
expected; patients <9 months from the initial diagnosis of 
non-ischemic CM with syncope that is thought to be due 
to a ventricular tachyarrhythmia (by clinical history or 
documented non-sustained VT); and patients <9 months 
from the initial diagnosis of non-ischemic CM who have 
been listed for heart transplant or implanted with a left 
ventricular assist device. Of course, ICD implantation for 
secondary prevention is recommended for all patients with 
DCM who present with sustained (or hemodynamically 
significant) ventricular tachyarrhythmia, regardless of the 
time of diagnosis of the disease. 
Opposing the strategy of the waiting period and 
deferring ICD implantation comes from studies indicating 
that patients with DCM present a significant risk of major 
arrhythmic events in the first phase of the disease.29  
Among 952 patients with DCM included in the Heart 
Muscle Disease Registry of Trieste, 20 patients (2.1%) 
experienced SCD/malignant ventricular arrhythmias 
within the first 6 months after enrollment.29  At baseline, 
these patients showed a worse functional class (NYHA 
class III-IV 42% vs 22%, p = 0.038), a longer QRS 
complex duration (127 + 41 ms vs 108 + 33 ms; p = 0.013) 
and a larger indexed LV end-systolic volume (82 + 49 
ml/m2 vs 67 + 34 ml/m2; p = 0.049). Beta-blockers were 
less tolerated (59% vs. 83%; p = 0.008), mostly due to 
hemodynamic intolerance. At multivariate analysis, LV 
end-diastolic volume index (odds ratio -OR: 1.012; p = 
0.043) and QRS complex duration (OR: 1.017; p = 0.015) 
were independently associated with early occurrence of 
arrhythmias, whereas beta-blockers demonstrated a 
protective effect (OR: 0.169; p = 0.006). Another study 
indicated that patients with nonischemic DCM 
experienced equivalent occurrences of treated and 
potentially lethal arrhythmias irrespective of diagnosis 
duration.27 Others suggest ICD implantation early after the 
initial diagnosis of DCM only in patients with positive 
LGE or patients with non-sustained VT.30  In the 
remainder, the wearable cardioverter defibrillator may 
play a role as a bridge to ICD decision.  
 According to an American Appropriate Use Criteria 
report,31 a most appropriate indication for ICD 
implantation for primary prevention of SCD in non-
ischemic DCM patients includes patients with LVEF 
<35%, NYHA class I-III who have been on optimal 
therapy for at least 3 months. A “may be appropriate” 
indication comprises patients with a newly diagnosed 
ischemic DCM with narrow QRS, an LVEF < 30% and 
class II-III symptoms. Also, appropriate indications for 
ICD implantation comprise patients with LVEF <35% and 
specific types of cardiomyopathies, such as sarcoid heart 
disease, myotonic dystrophy or Chagas disease, or 
peripartum cardiomyopathy that persists >3 months post-
partum, or giant cell myocarditis of any LVEF. For CRT-
D implantation, appropriate patients would be considered 
those with non-ischemic DCM, sinus rhythm, LVEF 
<35%, QRS >150 ms, LBBB and NYHA II/III/ ambulato-
ry IV; or non-LBBB, NYHA III / ambulatory IV; or QRS 
120-149 ms, LBBB and NYHA class II, III/ambulatory IV.  
With regards to cost-effectiveness, a recent analysis 
documented the cost-efficacy of implantable cardiac 
devices in patients with systolic heart failure, with CRT-D 
remaining the most cost-effective choice in a much wider 
group.32 Specifically, according to data from 13 
randomized trials, at a threshold of £30,000 per QALY 
gained, CRT-D was cost-effective in 10 of the 24 
subgroups including all LBBB morphology patients with 
NYHA class I-III. ICD was cost-effective for all non-
NYHA IV patients with QRS duration <120 ms and for 
NYHA I-II non-LBBB morphology patients with QRS 
duration 120-149 ms. CRT-P was also cost-effective in all 
NYHA III-IV patients with QRS duration >120 ms. Device 
therapy is cost-effective in most patient groups with LBBB 
at a threshold of £20,000 per QALY gained.  
According to a systematic review of clinical trials of 
non-ischemic DCM and the use of ICDs and cardiac 
magnetic resonance imaging with late gadolinium 
enhancement (LGE) for risk stratification, LGE can 
identify patients with non-ischemic DCM who are at high 
risk for SCD and may enable optimized patient selection 
for ICD placement.26 On the other hand, the absence of 
LGE may reduce the need for ICD implantation in patients 
with NIDM who are at low risk for future VF/VT or SCD.   
Similar findings were recently confirmed by a new 
systematic review and meta-analysis of 29 studies 
comprising 2,948 patients with DCM and LVEF 20-43%, 
stratified by the presence or absence of LGE.33 LGE was 
significantly associated with the arrhythmic endpoint 
(ventricular arrhythmias or SCD) both in the overall 
population (odds ratio: 4.3; p < 0.001) and when including 
only those studies that performed multivariate analysis 
(hazard ratio: 6.7; p <0.001). The association between 
LGE and the arrhythmic endpoint remained significant 
among studies with mean LVEF >35% (odds ratio-OR: 
5.2; p < 0.001) and was maximal in studies that included 
only patients with primary prevention ICDs (OR: 7.8; p = 
0.008). The authors concluded that LGE could be a 
powerful tool to improve risk stratification for SCD in 
patients with DCM, while 2 major questions need to be 
addressed in future studies: whether patients with LGE 
could benefit from primary prevention ICDs irrespective 
of their LVEF, while patients without LGE might not need 




Table 1. Randomized Controlled Trials of Primary 
Prevention ICD Therapy in Patients with DCM 
 
Study/year Pts Inclusion Criteria Results 
CAT / 20029 104 DCM ≤9 mos 
LVEF ≤30% 
Randomized to ICD or 
no ICD 
No difference in 
mortality between 
groups at up to 4 y 






Randomized to either 
amiodarone or ICD 
No difference 
between groups in 
overall mortality 
or quality of life. 
Trend to improved 
arrhythmia-free 
survival & lower 




PVCs or NSVT 
Randomized to ICD + 
medical therapy or 
medical therapy alone 
Significant ↓ in 
sudden death in 
the ICD group 
(hazard ratio 0.2) 




1520 NYHA III-IV 
Ischemic or 
nonischemic 
QRS ≥ 120 ms 
Randomized to optimal 
pharmacological therapy 
alone, or in combination 
with CRT-P or CRT-D 
(1:2:2 ratio) 
c/t optimal drug 
therapy alone, 
CRT-D (& CRT-
P) ↓time to death 
or hospitalization 
for any cause. 
CRT-D (but not 




2521 NYHA II-III 
LVEF ≤35% 
52% ischemic, 48% 
nonischemic 
cause of LV impairment 
Randomized to (i) 
conventional therapy + 
placebo, (ii) 
conventional therapy + 
amiodarone or 
(iii) conservative 
therapy + ICD 
ICD therapy was 
a/w 23% ↓ in risk 
of death and an 
absolute mortality 
decrease of 7.2% 
after 5 years 
(results did not 
vary according to 
cause of CM). No 
difference between 
amiodarone and 




1116 NYHA class II - IV  
LVEF ≤35%  
NT-proBNP >200 pg/ml  
ICD (n=556) vs usual 
clinical care (n=560) 
At 67.6 mos: 120 
deaths (21.6%) in 
ICD gp & 131 
(23.4%) in control 
gp (HR, 0.87; P = 
NS). SCD in 24 
pts (4.3%) in ICD 
gp & in 46 pts 
(8.2%) in control 
gp (HR, 0.50; 
P=0.005)  
 
a/w = associated with; CM = cardiomyopathy; CRT = cardiac 
resynchronization therapy; c/t = compared to; DCM = dilated 
cardiomyopathy; gp = group; HR = hazard ratio; ICD = implantable 
cardioverter defibrillator; LV = left ventricular; LVEF = left ventricular 
ejection fraction; mos = months; NSVT = non-sustained ventricular 
tachycardia; NYHA = New York Heart Association; pts = patients; 





Table 2. Current Guidelines for ICD/CRT Implantation 
in Patients with DCM  
 
Guidelines Indication Class / LOE Device Comments 
ACC/AHA/ 
HRS 2008/ 
2012 2, 3  
DCM,  
LVEF ≤35%,  
NYHA II-III 
I / B ICD  
DCM, LVEF 
≤35%, SUO  
IIa / C ICD  
DCM, LVEF 
≤35%,NYHA I 
IIb / C  ICD  
LVEF <35%, 
LBBB,  
NYHA II-IV,  
QRS > 150 ms  
● I/A (SR) 
(NYHA III-IV) 
● I/B (SR) 
(NYHA II) 
● IIa / B (AF) 
● IIa / A (non-





LBBB / NYHA 









IIa / B (SR) 







ESC 2013/  
2015/2016 
4-6 
LVEF ≤35%  
NYHA II–III  
≥3 mos OMT 
I / B ICD  
LVEF <35%, 
SR, LBBB, 
QRS >150 ms 






LVEF <35%,  
● NYHA I-III, 
QRS < 120 ms 
 ICD NYHA IV: 
ICD & CRT 
not indicated 
● NYHA I-III, 
QRS 120-149, 
non-LBBB 
● NYHA I, 
LBBB 
 ICD NYHA IV: 
CRT-P 
● NYHA II-III, 
QRS 120-149 
ms, LBBB 
 CRT-D NYHA I: ICD 
NYHA IV: 
CRT-P 
● NYHA I-III, 
QRS >150 ms 
 CRT-D NYHA IV: 
CRT-P  
* file:///D:/SCD/CM/NICE%20guidelines%202014.pdf  
AF = atrial fibrillation; CRT = cardiac resynchronization therapy; CRT-D = 
CRT-defibrillator; CRT-P = CRT-pacemaker; DCM = dilated cardiomyopathy; 
ICD = implantable cardioverter defibrillator; LBBB = left bundle branch block; 
LOE = level of evidence; LVEF = left ventricular ejection fraction; NYHA = 
New York Heart Association; OMT = optimal medical therapy; SR = sinus 
rhythm; SUO = syncope of unknown origin   
Conclusion 
 Risk stratification for SCD in non-ischemic DCM 
remains a difficult task. Device (ICD or CRT) implantation 
that effectively prevents SCD in this population is 
currently guided by left ventricular ejection fraction, 
severity of heart failure symptoms according to NYHA 
classification, and the morphology and duration of the 
QRS complex. The results of a recent study stirred some 
initial controversy with regards to the utility of the ICD in 
these patients, however, a subsequent meta-analysis 
confirmed prior findings of the survival-prolonging benefit 
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conferred by device therapy. Newer findings with use of 
LGE CMR detecting myocardial fibrosis are encouraging 
in risk stratifying patients in an attempt to circumvent the 
limitations of relying mainly on a LVEF <35% which is 
currently considered the gold-standard approach.   
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